SCHEMBL1287442

SCHEMBL1287442

CC1(C)OCC(NS(=O)(=O)c2ccc(Cl)cc2)CO1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.48
APP P05067 1/20 0.48
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA12 O43570 1/20 0.46
CA3 P07451 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA13 Q8N1Q1 1/20 0.46
CA14 Q9ULX7 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
KDM4E B2RXH2 1/20 0.45
RECQL P46063 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
HSP90AA1 P07900 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178427 0.77 KDM4E (0.68) HTTCA1CA2CA12CA3
SCHEMBL1287277 0.75 ALDH1A1 (0.59) HTTKMT2APSEN1PSEN2APH1B
SCHEMBL14842266 0.74 SMN1; SMN2 (0.75) HTTKDM4ERECQLSMN1; SMN2KMT2A
SCHEMBL7893069 0.74 SMN1; SMN2 (0.81) HTTKDM4ERECQLSMN1; SMN2KMT2A
SCHEMBL14842518 0.73 KDM4E (0.58) HTTKDM4ERECQLSMN1; SMN2KMT2A
SCHEMBL7562761 0.72 SMN1; SMN2 (0.79) HTTKDM4ERECQLSMN1; SMN2KMT2A
SCHEMBL6928447 0.70 KDM4E (0.58) HTTCA1CA2CA12CA3
SCHEMBL6928450 0.70 KDM4E (0.58) HTTKDM4ERECQLSMN1; SMN2KMT2A
SCHEMBL9015423 0.70 KDM4E (0.58) HTTCA1CA2KDM4ERECQL
SCHEMBL9015380 0.70 KDM4E (0.58) HTTKDM4ERECQLSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310384-A1 Sulfonamide-Containing Compounds THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-11-21 US disclosed
WO-2012047926-A2 SULFONAMIDE-CONTAINING COMPOUNDS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310384-A1 Sulfonamide-Containing Compounds BACE1, BACE2, GSAP HTT 259/4885APP 6/4885CA1 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.